Gluz, O., Kuemmel, S., Nitz, U., Braun, M. W., Luedtke-Heckenkamp, K., Darsow, M., Forstbauer, H., Aktas, B., Grischke, E., Schumacher, C., Reimer, T., Malter, W., Nuding, B., Wuerstlein, R., Christgen, M., Kreipe, H. H., Kates, R. E., Eulenburg, C. Z., Baehner, R., Harbeck, N. (2026). Role of neoadjuvant versus adjuvant chemotherapy, dose density, and treatment schedule in biologically high-risk HR+/HER2- breast cancer: A pooled analysis of the WSG ADAPT-HR+/HER2- and PlanB trials.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.17_suppl.lba515